Aisling Capital Management LP

CIK 0001766721 · NEW YORK, NY · Quarter end: 2026-06-30 · Filed on: 2026-08-13 · Open the SEC source

Aisling Capital Management LP reported 14 positions worth $471.6M as of June 30, 2026 (13F filed August 13, 2026). Largest holding: BBIO (72.5%).

Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$471.6M
2026 Q2
Positions
14
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
99.0%
Est. Net Flow (Q)
2026 Q2
10 / 14 positions shown
#SymbolCompanyTypeValue% Port.Shares1YYTD
1BBIOBRIDGEBIO PHARMA INCSH$341.8M72.48%4,589,611
2GLUEMONTE ROSA THERAPEUTICS INCSH$37.6M7.98%1,555,664
3SNDXSYNDAX PHARMACEUTICALS INCSH$28.8M6.10%1,316,806
4CMPSCOMPASS PATHWAYS PLCSH$20.3M4.30%1,432,336
5BCAXBICARA THERAPEUTICS INCSH$16.9M3.58%568,919
6BBOTBRIDGEBIO ONCOLOGY THERAPEUTSH$7.8M1.64%1,018,018
7SRRKSCHOLAR ROCK HLDG CORPSH$4.2M0.90%77,031
8URGNUROGEN PHARMA LTDSH$4.0M0.84%108,000
9BMEABIOMEA FUSION INCSH$3.0M0.64%2,048,757
10ACRSACLARIS THERAPEUTICS INCSH$2.3M0.49%434,455

The free plan shows the top 10 positions. The remaining 4 positions, the full portfolio and quarter changes unlock with Pro.

Pro Feature

This section is exclusive to Fundocap Pro. Full holdings tables, consensus trades, ownership analysis, backtests and exports unlock with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

Frequently Asked Questions

What stocks does Aisling Capital Management LP hold as of Q2 2026?

Aisling Capital Management LP reported 14 positions worth $471.6M in its Q2 2026 13F filing. Largest positions: BBIO (72.5%), GLUE (8.0%), SNDX (6.1%), CMPS (4.3%) and BCAX (3.6%).

What did Aisling Capital Management LP buy in Q2 2026?

No previous quarter is available yet; the comparison appears with the next filing.

What did Aisling Capital Management LP sell in Q2 2026?

No previous quarter is available yet.

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.